New Focus Expands Cancer, Kidney and Vascular Research to Drug Development
Programs
SEATTLE, June 8 /PRNewswire/ -- Thomas O. Daniel, M.D., is the new vice
president of vascular biology, discovery research, at Immunex Corporation
(Nasdaq: IMNX), the company announced today. Dr. Daniel is building the new
vascular biology department at the company, utilizing his broad background and
expertise in the areas of cancer, renal and vascular biology.
Prior to joining Immunex, Dr. Daniel was Director of the Vanderbilt
University Center for Vascular Biology and Professor of Medicine and Cell
Biology. He received a B.A. in Chemistry from Southern Methodist University,
Dallas, TX and an M.D. from University of Texas Southwestern Medical School,
Dallas, TX.
"We are powering up research and development programs at Immunex in the
field of vascular biology, which expands our ability to develop new treatments
in the areas of cancer, cardiovascular and other diseases," said Doug
Williams, Ph.D., chief technology officer and executive vice president. "We
have collaborated with Dr. Daniel extensively since 1995 in defining molecular
controls for cancer angiogenesis and thrombosis. His background,
accomplishments and enthusiasm are a great asset to Immunex and its
shareholders."
During his career he has received numerous awards and honors such as being
named Associate/Assistant Investigator to the Howard Hughes Medical Institute
and being named the Catherine McLaughlin Hakim Chair of Medicine. He has
served on various committees for the American Society of Nephrology and on the
editorial board for the American Journal of Kidney Diseases.
Immunex Corporation is a biopharmaceutical company dedicated to developing
immune system science to protect human health. The company's products offer
hope to patients with cancer, inflammatory and infectious diseases.
American Home Products Corporation owns a majority interest in Immunex.
AHP is one of the world's largest research-based pharmaceutical and health
care products companies. It is a leader in the discovery, development,
manufacturing and marketing of prescription drugs, including biotechnological
and vaccine products, animal health care products and over-the-counter
medications.
NOTE: This news release contains forward-looking statements that involve
risks and uncertainties, including risks associated with clinical development,
regulatory approvals, product commercialization and other risks described from
time to time in the SEC reports filed by Immunex, including the most recently
filed Form 10-K and 10-Q.
An electronic version of this news release -- as well as additional
information about Immunex of interest to investors, customers, future
employees and patients -- is available on the Immunex home page at
http://www.immunex.com.
SOURCE Immunex Corporation
 back to top
Related links:
http://www.immunex.com
Company News On-Call:
http://www.prnewswire.com/comp/434644.html or fax,
800-758-5804, ext. 434644
CONTACT:
media, Pam Rabe, 206-470-4131, or investors,
Mark Leahy, 206-389-4363, both of Immunex
|
